Ali Al-Janabi

Ali Al-Janabi

Auto-generated profile, based on publicly available information

Ali Al-Janabi

Northern Care Alliance NHS Foundation Trust, Dermatology Centre , Salford

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 January 2020 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Closed access
PDF file
AAA. Al‐Janabi
A. Al‐Janabi
AFA.C. Foulkes
A.C. Foulkes
KMK. Mason
K. Mason
CSC.H. Smith
C.H. Smith
CGC.E.M. Griffiths
C.E.M. Griffiths
RWR.B. Warren
R.B. Warren

1 January 2024 in JAMA Dermatology
Verified
Journal Article
Open access
PDF file
AAAli Al-Janabi
Ali Al-Janabi
OAOras A. Alabas
Oras A. Alabas
ZYZenas Z. N. Yiu
Zenas Z. N. Yiu
AFAmy C. Foulkes
Amy C. Foulkes
SESteve Eyre
Steve Eyre
VZVera Zietemann
Vera Zietemann
While biologics targeting tumor necrosis factor (TNF), interleukin (IL) 12/23, IL-17, and IL-23 are highly effective treatments for plaque psoriasis, they are associated with cutaneous adverse events, such as paradoxical psoriasis,1 cutaneous lupus, and granulomatous disorders.2 Some patients with psoriasis develop paradoxical eczema, an atopic dermatitis (AD) phenotype, during biologic exposure3 because these dermatoses are genetically and immunologically divergent and rarely occur together4-7; 1 meta-analysis identified a 2% prevalence of AD in those with psoriasis.8 Furthermore, there have been reports of psoriasis or inflammatory arthritis developing secondary to IL-4/13 inhibitors used for AD.9,10

1 January 2022 in Psoriasis: Targets and Therapy
Verified
Journal Article
Open access
PDF file
AAA Al-Janabi
A Al-Janabi
ZYZzn Yiu
Zzn Yiu
Biologics targeting Th1/Th17 cytokines have revolutionised psoriasis treatment. In addition to treatment effectiveness, it is important to define and understand the long-term risks of biologic therapy in order to guide therapy selection and minimise these risks for patients where possible. This review article summarises available evidence from trial data, observational studies and pharmacovigilance registries to explore key long-term risks of biologic treatment, and how these risks might be managed in clinical practice.

12 May 2021 in British Journal of Dermatology
Verified
Journal Article
Open access
PDF file
AAA. Al‐Janabi
A. Al‐Janabi
ZLZ. Littlewood
Z. Littlewood
Chris EM GriffithsChris EM Griffiths
Chris EM Griffiths
HHH.J.A. Hunter
H.J.A. Hunter
HCH. Chinoy
H. Chinoy
RWR.B. Warren
R.B. Warren
There are few data on whether immunomodulator therapy attenuates humoral response to vaccines for severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). Some vaccines require two doses for maximum protection, with international variation in dosing schedules. A 3 month interval between doses is being used in the U.K. We evaluated antibody titres to SARS‐CoV‐2 following initial‐dose BNT162b2 (Pfizer/BioNTech) or AZD1222 (AstraZeneca) vaccines in adults with psoriasis and other immune‐mediated inflammatory diseases (IMIDs) receiving biologic and/or oral non‐biologic immunomodulators.

3 May 2021 in British Journal of Dermatology
Verified
Journal Article
Open access
PDF file
WHW.Y. Haw
W.Y. Haw
AAA. Al‐Janabi
A. Al‐Janabi
BAB.W.M. Arents
B.W.M. Arents
LAL. Asfour
L. Asfour
LEL.S. Exton
L.S. Exton
ZYZ.Z.N. Yiu
Z.Z.N. Yiu
Introduction Clinical practice guidelines (CPGs), statements that include recommendations intended to optimise patient care, play a critical role in standardising and improving treatment outcomes based on best evidence. It is currently unclear how many CPGs are available globally to assist clinicians in the management of patients with skin disease. Objective Our aim was to search for and identify CPGs for dermatological conditions with the highest burden globally. Methods We adapted a list of 12 dermatological conditions with the highest burden from the Global Burden of Disease (GBD) study 2019. A broad systematic literature search was conducted to identify CPGs published between October 2014 to October 2019. The scoping review was conducted and reported in accordance with the PRISMA framework. Results A total of 226 CPGs were included. Melanoma had the greatest representation in the CPGs, followed by dermatitis and psoriasis. Skin cancers had the highest CPGs representation overall but with lower GBD disease burden ranking. There was an uneven distribution by geographical region, with resource‐poor settings being under‐represented. The CPGs’ skin disease categories correlated weakly with the GBD disability‐adjusted life‐years metrics. 89 CPGs did not have funding disclosures and 34 CPGs were behind a paywall. Conclusion The global production of dermatology CPGs showed wide variation in geographical representation, article accessibility and funding reporting. The number of skin disease CPGs were not commensurate with its disease burden. Future work will critically appraise the methodology and quality of dermatology CPGs and lead to the production of an accessible online resource summarising these findings.

10 March 2022 in Clinical and Experimental Dermatology
Verified
Journal Article
Open access
PDF file
AAAli Al-Janabi
Ali Al-Janabi
AFAmy Charlotte Foulkes
Amy Charlotte Foulkes
Chris EM GriffithsChris EM Griffiths
Chris EM Griffiths
RWRichard Bruce Warren
Richard Bruce Warren
Summary: Atopic eczema and psoriasis are chronic, inflammatory dermatoses that can significantly affect the quality of life of those affected. Although both diseases are common, they rarely occur together. Severe psoriasis can be treated with biologic therapies targeting specific cytokine pathways involved in disease pathogenesis. There are reports of paradoxical eczema developing in biologic-treated patients with psoriasis, sometimes necessitating treatment discontinuation and thus leading to poor disease control. This retrospective case series identified 36 such events occurring in 23 patients. All currently available biologic classes were implicated. Eosinophilia (n = 19) and elevated serum IgE (n = 3) were identified in some cases. Treatment strategies included no treatment, topical corticosteroids, broad-acting systemic agents, and discontinuation or switch of biologic therapy. Two patients had persistent eczema and psoriasis despite discontinuation of all biologic therapies.